We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Dr
Laura
Coates
+44 (0)1865 737905
laura.coates@ndorms.ox.ac.uk
More information about this study, what is involved and how to take part can be found on the study website.
Psoriatic arthritis
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Psoriatic arthritis (PsA) is a type of inflammatory arthritis that can cause pain and joint damage if left untreated. We have already shown that a ‘Treat to Target’ approach where treatment is increased until a target was achieved for the patients for improved arthritis, psoriasis, quality of life, pain and function. However, there are no studies looking at which drugs work best in this ‘Treat to Target’ approach. The usual strategy is ‘step-up’ approach for all patients, whether they have mild or severe disease. This means at first one standard arthritis drug is used, then two standard drugs together and finally newer stronger biologic drugs for patients not responding to the other drugs. Previous studies in patients with severe disease suggested they may do better if they are treated with stronger drugs earlier. So the aim of this study is to see if patients with moderate to severe PsA do better if they start treatment with two drugs together at the beginning of their treatment or if they start on a biologic drug from the beginning.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
2024 Protocol article in https://pubmed.ncbi.nlm.nih.gov/38826570/ (added 28/02/2025)
You can take part if:
You may not be able to take part if:
1. Previous treatment for articular disease with disease modifying drugs (DMARDs) including, but not limited to, methotrexate, sulfasalazine, leflunomide and ciclosporin2. Female patient who is pregnant, breast-feeding or planning pregnancy during the course of the trial.3. Significant renal or hepatic impairment.4. Patients who test positive for Hepatitis B, C or HIV.5. Contraindication to any of the investigative drugs.6. Currently abuse drugs or alcohol7. Scheduled elective surgery or other procedures requiring general anaesthesia during the trial.8. Life expectancy of less than 6 months.9. Any other significant disease or disorder which, in the opinion of the Investigator, may either put patients at risk because of participation in the trial, or may influence the result of the trial, or their ability to participate in the trial.10. Participation in another research trial involving an investigational product in the past 12 weeks.11. Additional exclusion criteria apply to patients randomised to arm 3 and receiving adalimumab therapy:11.1 Active tuberculosis (TB), chronic viral infections, recent serious bacterial infections, those receiving live vaccinations within 3 months of the anticipated first dose of study medication, or those with chronic illnesses that would, in the opinion of the investigator, put the participant at risk. 11.2 Latent TB unless they have received appropriate anti-tuberculous treatment as per local guidelines11.3 History of cancer in the last 5 years, other than non-melanoma skin cell cancers cured by local resection or carcinoma in situ.
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Dr
Laura
Coates
+44 (0)1865 737905
laura.coates@ndorms.ox.ac.uk
More information about this study, what is involved and how to take part can be found on the study website.
The study is sponsored by University of Oxford and funded by NIHR Academy; Grant Codes: CS-2016-16-016.
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
